CN115515985A - 生物大分子靶向特异性补体抑制剂及其制备方法与应用 - Google Patents

生物大分子靶向特异性补体抑制剂及其制备方法与应用 Download PDF

Info

Publication number
CN115515985A
CN115515985A CN202180034009.2A CN202180034009A CN115515985A CN 115515985 A CN115515985 A CN 115515985A CN 202180034009 A CN202180034009 A CN 202180034009A CN 115515985 A CN115515985 A CN 115515985A
Authority
CN
China
Prior art keywords
domain
fusion protein
crig
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034009.2A
Other languages
English (en)
Inventor
李录英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Original Assignee
Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kang Jing Bio Medical Science And Technology Co ltd filed Critical Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Publication of CN115515985A publication Critical patent/CN115515985A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种生物大分子靶向特异性补体抑制剂的融合蛋白，其包含：(i)CRIg胞外结构域，(ii)补体抑制结构域和(iii)增效结构域，该融合蛋白的制备方法和用途，以及包含该融合蛋白的药物组合物。该融合蛋白不但具有明显的靶向性补体抑制效果，而且有利于增加成药性和/或生产，可用于多种与补体异常激活有关的人类疾病的治疗和预防。

Description

PCT国内申请，说明书已公开。

Claims (41)

  1. PCT国内申请，权利要求书已公开。
CN202180034009.2A 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用 Pending CN115515985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010393721.9A CN113637084A (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN2020103937219 2020-05-11
PCT/CN2021/092861 WO2021228052A1 (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Publications (1)

Publication Number Publication Date
CN115515985A true CN115515985A (zh) 2022-12-23

Family

ID=78415417

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010393721.9A Pending CN113637084A (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN202180034009.2A Pending CN115515985A (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010393721.9A Pending CN113637084A (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Country Status (6)

Country Link
US (1) US20230348554A1 (zh)
EP (1) EP4151659A1 (zh)
JP (1) JP2023526218A (zh)
CN (2) CN113637084A (zh)
CA (1) CA3178088A1 (zh)
WO (1) WO2021228052A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920849A (zh) * 2022-03-09 2022-08-19 安徽省立医院(中国科学技术大学附属第一医院) 一种靶向补体免疫抑制蛋白及其构建方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
RU2536937C2 (ru) * 2008-10-14 2014-12-27 Дженентек, Инк. Варианты иммуноглобулина и их применения
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
CN106928371B (zh) * 2015-12-31 2021-06-08 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用

Also Published As

Publication number Publication date
CA3178088A1 (en) 2021-11-18
EP4151659A1 (en) 2023-03-22
WO2021228052A1 (zh) 2021-11-18
US20230348554A1 (en) 2023-11-02
CN113637084A (zh) 2021-11-12
JP2023526218A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
KR100391227B1 (ko) 인체의 프로그램화 된 세포사멸과 관련있는 펩티드 및 이를 암호하는 디엔에이(dna)
JP5902367B2 (ja) 抗体
JP6938565B2 (ja) Ｕｔｉ融合タンパク質
JP7306655B2 (ja) Ｉｌ－３７バリアント
JP2006505243A (ja) Ｍｃｐタンパク質の新規のアンタゴニスト
JP2002537796A (ja) ヒトグリコシル化酵素
CN115515985A (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
BG107685A (bg) Хемокинови мутанти за лечение на мултиплена склероза
US7465453B2 (en) Polypeptide fragments of CKLF1
US11697682B2 (en) Motile sperm domain containing protein 2 antibodies and methods of use thereof
JP2006502697A (ja) Ｆａｌｐタンパク質
JP3924330B2 (ja) 新規タンパク質、その遺伝子、アポトーシス誘導用試薬及び抗ガン剤
KR102315997B1 (ko) Baf57 재조합 융합 단백질 및 이의 용도
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7749758B2 (en) Human and mammalian stem cell-derived neuron survival factors
US7635576B2 (en) CC-chemokine binding tick proteins
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
EP1467752A1 (en) HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS
JP4025853B2 (ja) 新規蛋白質及びその製造方法
WO2001038375A1 (fr) Nouveau polypeptide, proteine a doigt de zinc 58 et polynucleotide codant pour ce polypeptide
WO2001030840A1 (fr) Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001023423A1 (fr) Nouveau gene comprenant le domaine ww et codant le polypeptide humain interagissant avec l'huntingtine, methode de production dudit gene et application correspondante

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084870

Country of ref document: HK